## **Perioperative Medicine Cardiology Consultation; Hypertension**



## CARDIOVASCULAR CENTER Wook Bum Pyun M.D., Ph.D. 심장혈관센타



Ewha Womans University, school of Medicine Cardiology department



Cardiac events such as myocardial infarction, Cardiac death occurred **1-5 %** of Unselected patients Undergoing non-cardiac surgery

Hypertension; common, avoidable

Surprisingly dark corner





#### 58 year-old man

Stomach cancer, curable stage with surgery Cardiologic consultations for pre-operative cardiovascular risk assessment and poor blood pressure control

148/92 mmHg

228/120 mmHg

168/104 mmHg 184/98 mmHg





Shall I go ahead and anaesthetize this patient with uncontrolled hypertension, or should I postpone surger 1?

Does t contro consec

Are pa increas it an

sure

Are there any data on which I can base my decision?





## 2008 국민건강통계

#### 국민건강영양조사 제4기 2차년도(2008)



※고혈압 유병률 : 수축기혈압이 140mmHg 이상이거나 이완기혈압이 90mmHg 이상 또는 혈압강하제를 복용한 분율, 만30세이상 ※2005년 추계인구로 연령표준화









## 2008 국민건강통계

#### 국민건강영양조사 제4기 2차년도(2008)

그림 37. 고혈압 관리현황



\*\*인지율 : 고혈압 유병자중 의사로부터 고혈압 진단을 받은 분율, 만30세이상 치료율 : 고혈압 유병자중 혈압강하제를 한달에 20일 이상 복용한 분율, 만30세이상 조절률(유병자기준) : 고혈압 유병자중 수축기혈압 140mmHg 미만이면서 이완기혈압 90mmHg 미만인 분율, 만30세이상 \*\*2005년 고혈압추정인구(2005년 추계인구×2005년 고혈압 유병률)로 연령표준화









## **HYPERTENSION**

## Perioperative Cardiovascular Risk Factor?





# Issues in anesthesia of patients with hypertension

50% prevalence in older than 65 years two thirds of elderly surgical patients 80% prevalence those who receive cardiac surgery
High unawareness, poor control rate
Significant contributor to postoperative risk
End-organ damage; heart, brain, kidney





## Hypertension & perioperative outcomes Hypertension

#### Hypotension, BP Lability, myocardial ischemia on ECG

Perioperative cardiac MI, mortality





Is having a diagnosis of hypertension of itself associated with increased perioperative risk, regardless of the arterial pressure at the time of admission to hospital for surgery?





## **Revised Cardiac Risk Index**

	Derivation S	Set (n=2893)	Validation S	Set (n=1422)
	Crude Data	Adjusted OR (95% Cl)	Crude Data	Adjusted OR (95% Cl)
Revised Cardiac Risk Index				
1. High-risk type of surgery	27/894 (3%)	2.8 (1.6, 4.9)	18/490 (4%)	2.6 (1.3, 5.3)
2. Ischemic heart disease	34/951 (4%)	2.4 (1.3, 4.2)	26/478 (5%)	3.8 <b>(</b> 1.7, 8.2)
3. History of congestive heart failure	23/434 (5%)	1.9 (1.1, 3.5)	19/255 (7%)	4.3 (2.1, 8.8)
4. History of cerebrovascular disease	17/291 (6%)	3.2 (1.8, 6.0)	10/140 (7%)	3.0 (1.3, 6.8)
5. Insulin therapy for diabetes	7/112 (6%)	3.0 (1.3, 7.1)	3/59 (5%)	1.0 (0.3, 3.8)
6. Preoperative serum creatinine $>$ 2.0 mg/dL	9/103 (9%)	3.0 (1.4, 6.8)	3/55 (5%)	0.9 (0.2, 3.3)

\*Based on logistic regression models including these 6 variables.







#### Is elevated arterial pressure at the time of admission for surgery associated with increased perioperative cardiac risk?

676 consecutive operations in patients >40 years old With mild to moderate hypertension



Perioperative lability and development cardiac arrhythmia, ischemia, failure and renal failure More important of intraoperative BP management than preoperative hypertension control



Goldman L, 1979



#### Several Issues interpreting these results

Absence of DBP>110 mmHg (5 patients) Limiting generalizability to the patients with poorly controlled hypertension Isolated Hypertension OR combined CAD





### The New England Journal of Medicine

©Copyright, 1990, by the Massachusetts Medical Society

Volume 323

**DECEMBER** 27, 1990

Number 26

#### ASSOCIATION OF PERIOPERATIVE MYOCARDIAL ISCHEMIA WITH CARDIAC MORBIDITY AND MORTALITY IN MEN UNDERGOING NONCARDIAC SURGERY

DENNIS T. MANGANO, PH.D., M.D., WARREN S. BROWNER, M.D., M.P.H., MILTON HOLLENBERG, M.D., MARTIN J. LONDON, M.D., JULIO F. TUBAU, M.D., IDA M. TATEO, M.S., AND THE STUDY OF PERIOPERATIVE ISCHEMIA RESEARCH GROUP\*





Table 3. Variables Associated with 83 Cardiac Outcomes among474 Patients Undergoing Noncardiac Surgery.			Table 4. Variables Associated with 15 Ischemic Events among 474 Patients Undergoing Noncardiac Surgery.         No. with				
			No. with Outcome and Variable/No.	Variable* Univariate models	Odds Ratio†	P VALUE	Outcome and Variable/No. with Variable
Variable*	Odds Ratio†	P VALUE	with Variable	History of claudication	3.4 (1.2-9.7)	0.02	9/150
Univariate models				Activity level ≥5‡ Preoperative use of nitrates	4.3 (1.2–16.0) 2.3 (0.83–6.6)	0.02 0.1	3/28 7/132
Previous myocardial infarction	1.7 (1.1-2.8)	0.03	38/167	Serum creatinine $\geq 177 \ \mu \text{mol}/$	5.0 (1.5–17.0)	0.004	4/35
Diabeti W	•			/pertensi em to be			12/167
110	n impo	orta	ant ri	sk factor ardial infa	of	n	Associated 9 Patients Iar Tachy- r Conges-
Vascular Narcotic anestnesia	2.2 (1.2-4.2)	0.01	10/04				P VALUE
Ischemia on Holter monitoring		0.01	10,01	Associated with congestive hear			
Before surgery‡	3.1 (1.8-5.3)	0.0001	28/84	History of dysrhythmia‡ Diabetes mellitus (treated	3.0 (1.4 2.4 (1.0		0.006 0.04
During surgery§	2.1 (1.2–3.7)	0.005	27/104	with medication) <sup>‡</sup>	2.4 (1.0	5-3.7)	0.04
After surgery¶ Multivariate model	3.3 (1.9-5.6)	0.0001	46/167	Duration of anesthesia and surger (per hour)§ or	ry 1.2 (1.1	1-1.4)	0.002
History of dysrhythmia	2.2 (1.3-3.9)	0.006	—	Vascular surgery‡	3.5 (1.6	5-7.9)	0.002
Preoperative use of digoxin for	3.3 (1.1–11.0)	0.04	—	Narcotic anesthesia§	2.5 (1.0	)-6.5)	0.05
congestive heart failure	19/11 20	0.02		or Isoflurane and narcotic anesthesia	a‡ 0.35 (0.1	(6-0.76)	0.008
Vascular surgery Ischemia on Holter monitoring	1.8 (1.1-3.2) 2.8 (1.6-4.9)	0.03 0.0002		Associated with ventricular tac	· · ·		2.2.2
after surgery	2.0 (1.0-7.7)	0.0002		Preoperative ischemia on Holter monitoring	7.8 (2.9	9-21)	0.0001
A MEDICAL CH				Preoperative use of digoxin for congestive heart failure	12.0 (2.8	350.0)	0.0009

### Common Practice to postpone surgery

## DBP>110 mmHg, SBP>180 mmHg

Increased risk of perioperative dysrhythmia myocardial ischemia, MI stroke



Prys-Roberts in 1971 Goldman and Caldera in 1979



# Pre-Operarive Blood Pressure

## Perioperative Cardiovascular Risk Factor?





ACC/AHA Perioperative Cardiovascular Evaluation For Non-cardiac Surgery



 Table 2. Clinical Predictors of Increased Perioperative

 Cardiovascular Risk (Myocardial Infarction, Heart Failure, Death)

Major

Unstable coronary syndromes

Acute or recent MI<sup>*a*</sup> with evidence of important

ischemic risk by clinical symptoms or noninvasive study

Unstable or severe<sup>b</sup> angina (Canadian Class III or IV)<sup>c</sup> Decompensated heart failure

Significant arrhythmias

High-grade atrioventricular block

Symptomatic ventricular arrhythmias in the presence of underlying heart disease

Supraventricular arrhythmias with uncontrolled ventricular rate

Severe valvular disease

Intermediate

Mild angina pectoris (Canadian Class I or II) Previous MI by history or pathological Q waves Compensated or prior heart failure Diabetes mellitus (particularly insulin-dependent) Renal insufficiency

Minor

Advanced age

Abnormal ECG (left ventricular hypertrophy, left bundle-branch block, ST-T abnormalities) Rhythm other than sinus (e.g., atrial fibrillation) Low functional capacity (e.g., inability to climb one flight of stairs with a bag of groceries) History of stroke Uncontrolled systemic hypertension



Journal of the American College of Cardiology © 2009 by the American College of Cardiology Foundation and the American Heart Association, Inc. Published by Elsevier Inc.

#### **PRACTICE GUIDELINES: FULL TEXT**

#### 2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and Society for Vascular Surgery

Numerous studies have shown that stage 1 or stage 2 hypertension (systolic blood pressure below 180 mm Hg and diastolic blood pressure below 110 mm Hg) is not an independent risk factor for perioperative cardiovascular complications.





#### The Dilemma of Immediate Preoperative Hypertension: To Treat and Operate, or to Postpone Surgery?

Patients with DBP 110 - 130 mmHg 400 patients; control group 589 patients the study group. The control group had their surgery postponed and they remained in hospital for BP control, and the study patients received 10 mg of nifedipine intranasally

Immediate preoperative reduction of DBP with intranasal nifedipine is safe in patients with wellcontrolled arterial hypertension but they presented with severe to very severe hypertension for patients in the OR. We were able to avoid unnecessary surgery postponement and attendant costs.





#### In stage 3 hypertension >180/110 mmHg

Stage 3 hypertension should be controlled before surgery. (2002) without reference

the potential benefits of delaying surgery to optimize the effects of antihypertensive medications should be weighed against the risk of delaying the surgical procedure. (2009)





### Intraoperative Systolic BP Variability

Excessive release of catecholamine Rapid intravascular volume shift Peripheral vasoconstriction Reduced baroreceptor sensitivity **Renin-angiotensin** activation Altered cardiac reflexes Inadequate anesthesia **Reperfusion** injury Aortic occlusive clamps Neural, humoral, cellular response





## Intraoperative Systolic BP Variability

Hyperinflammatory and procoagulation Platelet activation --- compromise microvascular flow

Perioperative hypertension increase myocardial O2 consumption LVEDP surgical bleeding

Perioperative hypotension subendocardial hypoperfusion--- myocardial ischemia





Systolic blood pressure variability episodes outside a blood pressure range (*e.g.*, higher than 135 or lower than 95 mmHg) were characterized by number of episodes, magnitude of episode, duration of episode, and magnitudeduration of excursion (*i.e.*, area under the curve).



## SWEET SPOT Target systolic blood pressure width 95 - 135 mmHg 75-135 AND 85-145 mmHg







#### Still difficult to hit or determine



# Anti-Hypertensive Drugs

## Perioperative Cardiovascular Risk Factor?





# Preoperative BP elevation

Exaggerated intraoperative BP fluctuation (blood pressure lability under anesthesia) ECG evidence of myocardial ischemia

## **Postoperative cardiac morbidity**





## Beta-blocker for preoperative high BP HR<50-60/min <80/min intraOP Modulate BP fluctuation Decrease perioperative myocardial ischemia Decrease postoperative atrial fibrillation

### Decrease cardiovascular complication Reduce mortality





#### Beta-blockers appear to be particularly attractive agents for the treatment of preoperative high blood pressure.

Table 1. Recommendations for Perioperative  $\beta$ -Blocker Therapy Based on Published Randomized Clinical Trials

	Low cardiac patient risk	Intermediate cardiac patient risk	CHD or high cardiac patient risk <sup>a</sup>
Vascular surgery	Class Iib Level of Evidence: C	Class IIb Level of Evidence: C	Class I <sup>b</sup> Level of Evidence: B Class IIa <sup>c</sup>
High-/intermediate-risk surgery	d	Class IIb	Level of Evidence: B Class IIa
Low-risk surgery	_d	Level of Evidence: C $\d^d$	Level of Evidence: B $\{d}^{d}$

#### preoperative testing. (Level of Evidence: B)

2. Beta blockers titrated to heart rate and blood pressure are reasonable for patients in whom preoperative assessment for vascular surgery identifies high cardiac risk, as defined by the presence of more than 1 clinical risk factor.<sup>‡‡</sup> (*Level of Evidence: C*)

3. Beta blockers titrated to heart rate and blood pressure are reasonable for patients in whom preoperative assessment identifies coronary artery disease or high cardiac risk, as defined by the presence of more than 1 clinical risk factor,<sup>‡‡</sup> who are undergoing intermediate-risk surgery (369). *(Level of Evidence: B)* 





#### Vasopressor system in BP regulation



Preoperative hypertension appear more likely to develop intraoperative hypotension than non-hypertensive persons

## ACE inhibitors and ARBs

suggested withholding ACE inhibitors and angiotensin receptor antagonists the morning of surgery





## Management of Hypertension during anesthesia

Antihypertensive medications be discontinued preoperatively Paradigm shift

> Most drugs that effectively BP control should be continued throughout the perioperative periods





Why anesthetist remained wary of Hypertension?

Hypertension; hemodynamic unstability myocardial ischemia Major risk factors of CAD, CHF, CVA, renal disease

Combined medical conditions and drugs





## **Preoperative Evaluation**

1. Adequacy of blood pressure control seems reasonable...

Make normotensive in hypertensive patients

For decreasing incidence of hypotension and myocardial ischemia





#### **Box. Hypertensive Comorbidities Associated** With Adverse Perioperative Outcomes

Occult coronary artery disease (Q waves on the electrocardiogram) Congestive heart failure

Left ventricular hypertrophy (voltage criteria)

Renal insufficiency (serum creatinine level >2.0 mg/dL [>176.8 µmol/L]) Cerebrovascular disease (history of cerebrovascular accident or transient ischemic attack)

3. Drugs and potential side effects ANS blocking drugs (alpha blocker) Exaggerate BP decrease due to blood loss positive pressure ventilation sudden position change Rebound hypertension in beta-blocker





### Induction of Anesthesia

 Rapidly acting IV drugs
 Direct laryngoscopy and tracheal intubation







### Maintenance of Anesthesia

To minimize wide fluctuation in blood pressure = control intra-op BP lability



Intraoperative hypertension painful stimulation in light anesthesia frequent in hypertension regardless of control volatile anesthesia is useful for BP control

Intraoperative hypotension control with depth of anesthesia and IV fluid





#### Postoperative



Require Prompt assessment and treatment To decrease myocardial ischemia, arrhythmia CHF, stroke, bleeding

PAIN control LABETALOL to oral agents





## CONCLUSIONS

Mild to moderate hypertension; no cardiovascular risk need not postpone surgery In high risk, **NOT CLEAR** consider risk of delay and operative risk Consider discontinue ACEI or ARB ??? Preferred results with beta-blockers in high risk Achieving hemodynamic stability (BP, HR)





## 경청해 주셔서 감사합니다.

















Risks of General Anesthesia and Elective Operation

#### in the Hypertensive Patient

tively) were not significantly different. Multivariate analysis of data for the patients with histories of hypertension showed that neither the preoperative in-hospital diastolic nor preoperative in-hospital systolic blood pressure values independently correlated with any of these three indices of perioperative blood pressure lability, with the development of cardiac arrhythmias, ischemia, or failure, or with postoperative renal Group I ( Group II failure. Effective intraoperative management may be more im-Group II. Group IV portant than preoperative hypertensive control in terms of de-Group V creasing clinically significant blood pressure lability and cardiovascular complications in patients who have mild to moderate GI; r hypertension. (Key words: Blood pressure: hypertension; G III; hypotension. Heart: arrhythmias; failure; infarction.)



## DBP<110 mmHg



HT

Per Cent

0.2

6

#### Is elevated arterial pressure at the time of admission for surgery associated with increased perioperative cardiac risk?

No significant difference in perioperative cardiac risk	Mean Preoperative Systolic Pressure*	Mean Intraoperative Systolic Pressure Nadir†	Patients with Perioperative Hypertensive Episodes‡		Patients Receiving Intraoperative Fluid Challenge or Adrenergic Agents to Maintain Blood Pressure§	
	$(torr \pm SEM)$	(torr ± SEM)	Number	Per Cent	Number	Per Cent
Group I (normotensive, no therapy) (n = 431) Group II (diuretics, no history of	126 ± 1	94 ± 1	33	8	82	19
hypertension) $(n = 49)$	$129 \pm 3$	$95 \pm 3$	3	6	9	18
Group III (now normotensive receiving therapy) (n = 79) Group IV (hypertensive despite	$136 \pm 2$	$100 \pm 2$	21	27	16	20
therapy) $(n = 40)$	$154 \pm 2$	$97 \pm 3$	10	25	13	33
Group V (untreated hypertension) (n = 77)	$161 \pm 2$	$98 \pm 2$	15	20	21	27

A linear trend was found for risk associated with increasing admission systolic blood pressure (odds ratio: 1.20 for each 10-mmHg increase in systolic pressure, 95% confidence intervals: 1.01-1.42).



